Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc.
Paris, May 30, 2024. Sanofi
announced today the completion of its acquisition of Inhibrx, Inc.
(“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to
Sanofi’s rare disease pipeline, underscoring the company’s
commitment to pursuing differentiated and potential best-in-class
medicines that build upon our existing strengths and
capabilities.
SAR447537 is a human recombinant protein that holds
the promise of allowing alpha-1 antitrypsin deficiency (AATD)
patients to achieve normalization of serum AAT levels with less
frequent (monthly vs. weekly) dosing. AATD is an inherited rare
disease characterized by low levels of AAT protein, predominantly
affecting the lung with progressive deterioration of the tissue.
SAR447537 may help to reduce inflammation and prevent further
deterioration of lung function in affected individuals.
The former holders of shares of Inhibrx common
stock voted to approve the acquisition at a special meeting of
stockholders on May 24, 2024. Upon the closing of the acquisition,
former shareholders of Inhibrx became entitled to receive $30.00
per share in cash, which represents a total equity value of
approximately $1.7 billion (on a fully diluted basis), as well as
one contingent value right per share to receive $5.00 upon the
achievement of a regulatory milestone.
Sanofi completed its acquisition of Inhibrx through
the merger of an indirect, wholly owned subsidiary of Sanofi with
and into Inhibrx, with Inhibrx continuing as the surviving
corporation and becoming an indirect, wholly owned subsidiary of
Sanofi.
Prior to the closing of the acquisition, Inhibrx
completed the spin-off of Inhibrx Biosciences, Inc. (“Inhibrx
Biosciences”), distributing 92% of Inhibrx Biosciences’s shares to
holders of shares of Inhibrx common stock as of May 17, 2024.
Inhibrx Biosciences, which was a wholly owned subsidiary of Inhibrx
prior to the distribution, acquired all of the assets of Inhibrx
not related to SAR447537, which include INBRX-109 and INBRX-1061,
as well as all Inhibrx employees, pursuant to an internal
reorganization. Inhibrx continues to own the remaining 8% of
Inhibrix Biosciences following the completion of the transactions.
Inhibrx Biosciences began trading on the NASDAQ Global Market on
May 30, 2024, under the ticker “INXB” and, beginning on May 31,
2024, will trade under the ticker “INBX”.
As of May 30, 2024, Inhibrx common stock will cease
to be traded on the NASDAQ Global Market and will be subsequently
deregistered.
Lazard acted as exclusive financial advisor to
Sanofi and Weil, Gotshal & Manges LLP acted as its legal
counsel. Centerview Partners LLC acted as exclusive financial
advisor to Inhibrx and Paul, Weiss, Rifkind, Wharton and Garrison
LLP served as legal counsel.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions. Sanofi is
listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comEvan Berland |
+1 215 432 0234 | evan.berland@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.comTimothy
Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor RelationsThomas Kudsk
Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.comAlizé
Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik Elgoutni| + 1 617
710 3587 | tarik.elgoutni@sanofi.comNathalie Pham
| + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions, and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2023. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Sanofi (TG:SNW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sanofi (TG:SNW)
Historical Stock Chart
From Oct 2023 to Oct 2024